Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital

BackgroundOff-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs.MethodsA nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring.ResultsA total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001).ConclusionsOLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs.

[1]  M. Bonati,et al.  Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil , 2008, European Journal of Clinical Pharmacology.

[2]  Epstein Rs,et al.  The many sides of off-label prescribing. , 2012 .

[3]  M. Pirmohamed,et al.  Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool , 2011, PloS one.

[4]  M. Danhof,et al.  Advances in paediatric pharmacokinetics , 2011, Expert opinion on drug metabolism & toxicology.

[5]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[6]  P. Tereskerz.  Appendix D: Pediatric research Equity Act of 2003 , 2012 .

[7]  M. Pirmohamed,et al.  Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes , 2009, PloS one.

[8]  J. Ford,et al.  Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence , 2013, BMC Pediatrics.

[9]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[10]  I. Choonara,et al.  Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective study , 1999, Acta paediatrica.

[11]  Munir Pirmohamed,et al.  Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature , 2011, European Journal of Clinical Pharmacology.

[12]  Pediatric Research Equity Act. , 2004, Journal of the National Cancer Institute.

[13]  E. Kimland,et al.  Off‐Label Drug Use in Pediatric Patients , 2012, Clinical pharmacology and therapeutics.

[14]  V. Fanos,et al.  Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety , 2006, Expert opinion on drug safety.

[15]  S-M Huang,et al.  The Many Sides of Off‐Label Prescribing , 2012, Clinical pharmacology and therapeutics.

[16]  Maurizio Bonati,et al.  Survey of unlicensed and off label drug use in paediatric wards in European countries , 2000, BMJ : British Medical Journal.

[17]  B. Hinz,et al.  The Impact of Unlicensed and Off-Label Drug Use on Adverse Drug Reactions in Paediatric Patients , 2004, Drug safety.

[18]  A. W. Lenderink,et al.  Risk factors for the development of adverse drug events in hospitalized patients , 2000, Pharmacy World and Science.

[19]  I. Heineck,et al.  Adverse drug reactions: a cohort study in internal medicine units at a university hospital , 2006, European Journal of Clinical Pharmacology.

[20]  D. Tibboel,et al.  A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. , 2001, Pediatrics.